Your email has been successfully added to our mailing list.

×
0 0.0611702127659574 -0.00531914893617022 0.0797872340425533 -0.0319148936170213 -0.074468085106383 -0.115691489361702 -0.0212765957446809
Stock impact report

aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

aTyr Pharma, Inc. (LIFE) 
Last atyr pharma, inc. earnings: 3/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: atyrpharma.com/investors-media
Company Research Source: GlobeNewswire
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications. “Many COVID-19 patients with severe disease experience serious, sometimes fatal, respiratory complications caused by an excessive inflammatory response in the lung, primarily driven by T-cells,” said Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The inflammatory lung injury related to COVID-19 may be similar to that of interstitial lung diseases, or ILDs, for which ATYR1923 is currently being investigated.” ATYR1923 has been shown pre-clinically to downregulate T-cell responses, thereby da Show less Read more
Impact Snapshot
Event Time:
LIFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for LIFE alerts
Opt-in for
LIFE alerts

from News Quantified
Opt-in for
LIFE alerts

from News Quantified